Armata Pharmaceuticals (ARMP) Net Income towards Common Stockholders: 2013-2024
Historic Net Income towards Common Stockholders for Armata Pharmaceuticals (ARMP) over the last 12 years, with Dec 2024 value amounting to -$53.2 million.
- Armata Pharmaceuticals' Net Income towards Common Stockholders fell 282.49% to -$8.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$16.0 million, marking a year-over-year decrease of 11.16%. This contributed to the annual value of -$53.2 million for FY2024, which is 22.71% down from last year.
- According to the latest figures from FY2024, Armata Pharmaceuticals' Net Income towards Common Stockholders is -$53.2 million, which was down 22.71% from -$43.3 million recorded in FY2023.
- In the past 5 years, Armata Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$22.2 million in FY2020 and a low of -$53.2 million during FY2024.
- In the last 3 years, Armata Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$43.3 million in 2023 and averaged -$44.5 million.
- Data for Armata Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY plummeted of 54.35% (in 2022) over the last 5 years.
- Armata Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at -$22.2 million in 2020, then dropped by 7.83% to -$23.9 million in 2021, then tumbled by 54.35% to -$36.9 million in 2022, then dropped by 17.39% to -$43.3 million in 2023, then fell by 22.71% to -$53.2 million in 2024.